
    
      Part A of the study is an interventional, double-blind, randomized, placebo-control design
      will be used to test safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in
      subjects ≥ 18 and ≤ 70 years of age with active diffuse cutaneous systemic sclerosis. The
      screening period is up to 28 days, with 84 days treatment period and 28 days follow-up off
      active treatment.

      Part B of the study is an interventional, open-label design will be used. All subjects who
      complete dosing in Part A without permanent discontinuation of study drug and who pass repeat
      safety screening will be eligible for enrollment. The screening period is up to 28 days, with
      a 364 day treatment period and 28 day follow up after last dose of JBT-101.
    
  